G2

G2GBIO, Inc.

Develops long-acting injectable therapies for chronic diseases and cancer.

456160 | KO

Overview

Corporate Details

ISIN(s):
N/A
LEI:
Country:
South Korea
Address:
충청북도 청주시 흥덕구 오송읍 의료단지길 21, 청주시
Sector:
Manufacturing
Industry:
Manufacture of pharmaceuticals, medicinal chemical and botanical products

Description

G2GBIO, Inc., founded in 2017, is a clinical-stage biotechnology company specializing in drug delivery systems (DDS) for long-acting injectables (LAI). The company develops advanced therapeutics using its proprietary InnoLAMP™ (Innovative Long-Acting MicroParticle) platform technology. This platform enables the creation of sustained-release microparticle formulations designed to improve medication convenience and patient adherence for chronic diseases. G2GBIO's development pipeline targets a range of therapeutic areas, including Alzheimer's disease, Type 2 diabetes, schizophrenia, and post-operative pain. A secondary platform, InteLAMP™, focuses on oncology treatments. The company supports its development with in-house GMP-certified research and pilot-scale production facilities.

This is a Fraction of the Available Data.

You're viewing a limited, static snapshot. Professionals use our API to get real-time, AI-ready data for G2GBIO, Inc. and 9,000+ other companies.

Stop analyzing yesterday's news. Start building a real-time advantage.

Request Enterprise API Access

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Date Filing Language Size Actions
2025-09-19 00:00
Share Issue/Capital Change
주식매수선택권행사
Korean 39.0 KB
2025-09-19 00:00
Major Shareholding Notification
주식등의대량보유상황보고서(일반)
Korean 380.4 KB
2025-09-19 00:00
Major Shareholding Notification
임원ㆍ주요주주특정증권등소유상황보고서
Korean 24.1 KB
2025-09-19 00:00
Major Shareholding Notification
임원ㆍ주요주주특정증권등소유상황보고서
Korean 24.9 KB
2025-09-19 00:00
Major Shareholding Notification
임원ㆍ주요주주특정증권등소유상황보고서
Korean 24.9 KB
2025-09-08 00:00
Major Shareholding Notification
[기재정정]주식등의대량보유상황보고서(일반)
Korean 859.0 KB

Automate Your Workflow. Get a real-time feed of all G2GBIO, Inc. filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

No Financial Data Available

Standardized financial statements for the selected period are not yet available.

Need More History? Access decades of standardized financials for G2GBIO, Inc. via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

Company Country Ticker View
KANABO GROUP PLC Logo
Develops cannabis formulas and vaporization devices for the medical and consumer wellness markets.
United Kingdom KNB
Kancera Logo
Develops small molecule drugs targeting the fractalkine axis for cancer and inflammatory diseases.
Sweden KAN
KANGSTEM BIOTECH CO., LTD. Logo
Develops stem cell therapies for rare diseases; offers culture media, cell platforms, and CDMO services.
South Korea 217730
Karo Pharma AB Logo
Develops and sells everyday healthcare products, focusing on OTC and skin health in Europe.
Sweden KARO
KBIO COMPANY Inc. Logo
Using a plant-based platform to rapidly develop biologics for public health.
South Korea 038530
Keeps Biopharma Inc. Logo
Develops cancer therapies and obesity drugs; manufactures industrial and cleanroom products.
South Korea 256940
Kidswell Bio Corporation Logo
Biopharma R&D of biosimilars, biologics, and cell therapies, with a pediatric focus.
Japan 4584
Kinarus Therapeutics Holding AG Logo
A specialty pharma firm developing and selling medicines for rare and specialty diseases.
Switzerland KNRS
KISSEI PHARMACEUTICAL CO.,LTD. Logo
Develops innovative drugs for urology, renal diseases, and rare or intractable diseases.
Japan 4547
Klaria Pharma Holding AB Logo
Develops oral films for non-invasive drug delivery as an alternative to injections and sprays.
Sweden KLAR

Talk to a Data Expert

Have a question? We'll get back to you promptly.